Anthrax Research Study

Currently Enrolling

Fighting Anthrax

Although Anthrax infection is rare in the United States, it can be deadly. Inhalation of Anthrax is the most lethal; without treatment only about 10-15% of those exposed survive.  Even with aggressive treatment, only 55% of people survive Anthrax infection.  Thus, it is very important to have strategies and treatment in place should an exposure occur.  One of the missions of the Department of Health and Human Services (HHS) is to develop and procure medical counter measures to address public health and medical consequences after Anthrax exposure. 

What This Study Involves

In 2015 the Food and Drug Administration (FDA) approved a vaccine for Anthrax prevention in adults ages 18 to 65. This vaccine has been used for pre-exposed individuals who are at high risk for the infection such military and lab worker.  The vaccine, BioThrax, causes the body to build up antibodies to fight the Anthrax bacteria and prevent illness. It has been shown the antibody responses to the vaccine diminish with age.  For example, a 30 year old will develop more immunity to Anthrax than a 60 year old when given the same dose. 

Our study will be comparing a younger group ages 18-50 to an older group ages 66-100 when receiving different does of BioThrax with and without an experimental additive.  We will be evaluating the safety and effectiveness (immune response) in each group. This 14 month study will consist of three vaccinations, 14 visits and blood draws.


Who is Eligible to Participate

To qualify you must be between the ages of 18-50 and 66-100 and in general good health. 

How to Participate

If you are interested in helping develop an Anthrax post-exposure treatment, please give us a call at 615-329-2222 between the hours of 7:30 – 4:30 Monday – Friday and 7:30-1:00PM on Friday.  Participates will receive compensation up to $1625 for time and travel.